Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Boehringer Ingelheim
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
National Cancer Institute (NCI)
Seagen Inc.
Filamon LTD
Varian, a Siemens Healthineers Company
Novartis
Fondazione del Piemonte per l'Oncologia
PMV Pharmaceuticals, Inc
AstraZeneca
Novartis
Fred Hutchinson Cancer Center
Kivu Bioscience Inc.
National Institutes of Health Clinical Center (CC)
University of Michigan Rogel Cancer Center
Eli Lilly and Company
UMC Utrecht
AstraZeneca
BeOne Medicines
National Institutes of Health Clinical Center (CC)
University of Chicago
Bayer
Psyence Australia Pty Ltd
University of California, Irvine
Eastern Cooperative Oncology Group
ViroMissile, Inc.
Terremoto Biosciences Inc.
Dana-Farber Cancer Institute
University Health Network, Toronto
Jazz Pharmaceuticals
National Institutes of Health Clinical Center (CC)
Washington University School of Medicine
University of Florida
M.D. Anderson Cancer Center
Myeloid Therapeutics
Tizona Therapeutics, Inc
Essen Biotech
Essen Biotech
Ulsan University Hospital
Angiex, Inc.
Memorial Sloan Kettering Cancer Center
Incyte Corporation
IDEAYA Biosciences
Baylor College of Medicine
University of Colorado, Denver
Abramson Cancer Center at Penn Medicine
UNC Lineberger Comprehensive Cancer Center
MacroGenics
Poitiers University Hospital